Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by c

Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"

California State Teachers Retirement System boosted its stake in shares of Dianthus Therapeutics, In

Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DN

Dimensional Fund Advisors LP lifted its position in Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 54

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.9 per share versus the Zacks

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.90) per share which missed the

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pat

DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active

DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active

NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:

Evercore ISI Group analyst Gavin Clark-Gartner maintains Dianthus Therapeutics (NASDAQ:DNTH) with

NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate cla

Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune

Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its C

Dianthus reports 75% responder rate for claseprubart in CIDP, while analysts say Sanofi's rilipr

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read

Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: D

Company announces $30 million Series A financing and founding leadership team with expertise in pulm

Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune

This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting ra

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; S

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.85) per share which beat the an

Wolfe Research analyst Andy Chen initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a

Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy

Wells Fargo analyst Sadia Rahman initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B.

Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about th

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

Raymond James analyst Steven Seedhouse upgrades Dianthus Therapeutics (NASDAQ:DNTH) from Outperfo

Baird analyst Joel Beatty maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and rai

Clear Street analyst Bill Maughan maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and ra

Dianthus announced that it has commenced an underwritten public offering of $400 million of shares o

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DN

Oppenheimer analyst Leland Gershell maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperfo

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

Dianthus Therapeutics shares jump after early success in a Phase 3 trial for CIDP treatment clasepru

Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(1.43) per share which missed the